In recent decades, SIX1 has been reported to be overexpressed in numerous human cancers, such as breast cancer 9, 10, ovarian cancer 11, colorectal cancer 12, thyroid carcinoma 13, and prostate cancer 14, leading to a more aggressive cell phenotype and poorer prognosis. Here, SIX1 is linked to colorectal cancer.